Journal article
Peroxisome proliferator-activated receptor gamma (PPARgamma) and colorectal carcinogenesis
Journal of cancer research and clinical oncology, Vol.133(12), pp.917-928
12/01/2007
DOI: 10.1007/s00432-007-0277-y
PMCID: PMC12160837
PMID: 17659359
Abstract
Peroxisome proliferator-activated receptor gamma (PPARgamma) a member of the nuclear transcription factor superfamily is playing a role in colon carcinogenesis. Although not all in vivo models agree, PPARgamma seems to have suppressive effects in this process favoring apoptosis and inhibiting the cell cycle by inducing expression of apoptosis and senescence proteins. With the recent discovery that anti-diabetic class of drugs thiazolidinediones act through activation of PPARgamma, interest in this transcription factor has increased as it can now be pharmacologically activated in order to obtain tumor suppression. In addition, thiazolidinediones and other PPARgamma agonists possess PPARgamma-independent anti-tumor effects. Although PPARgamma agonists may not by themselves be capable to induce clinical tumor regression, their combination with chemotherapy drugs or other targeted therapies is worth pursuing in the treatment of colorectal carcinoma.
Details
- Title: Subtitle
- Peroxisome proliferator-activated receptor gamma (PPARgamma) and colorectal carcinogenesis
- Creators
- Ioannis A Voutsadakis - University Hospital of Larissa
- Resource Type
- Journal article
- Publication Details
- Journal of cancer research and clinical oncology, Vol.133(12), pp.917-928
- DOI
- 10.1007/s00432-007-0277-y
- PMID
- 17659359
- PMCID
- PMC12160837
- NLM abbreviation
- J Cancer Res Clin Oncol
- ISSN
- 0171-5216
- eISSN
- 1432-1335
- Language
- English
- Date published
- 12/01/2007
- Academic Unit
- Internal Medicine
- Record Identifier
- 9984806502702771
Metrics
4 Record Views